{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:11:07Z","timestamp":1776132667634,"version":"3.50.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Infectious Diseases"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/s1473-3099(10)70319-4","type":"journal-article","created":{"date-parts":[[2011,4,30]],"date-time":"2011-04-30T19:38:10Z","timestamp":1304192290000},"page":"394-407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":206,"title":["European guidelines on the clinical management of HIV-1 tropism testing"],"prefix":"10.1016","volume":"11","author":[{"given":"LPR","family":"Vandekerckhove","sequence":"first","affiliation":[]},{"given":"AMJ","family":"Wensing","sequence":"additional","affiliation":[]},{"given":"R","family":"Kaiser","sequence":"additional","affiliation":[]},{"given":"F","family":"Brun-V\u00e9zinet","sequence":"additional","affiliation":[]},{"given":"B","family":"Clotet","sequence":"additional","affiliation":[]},{"given":"A","family":"De Luca","sequence":"additional","affiliation":[]},{"given":"S","family":"Dressler","sequence":"additional","affiliation":[]},{"given":"F","family":"Garcia","sequence":"additional","affiliation":[]},{"given":"AM","family":"Geretti","sequence":"additional","affiliation":[]},{"given":"T","family":"Klimkait","sequence":"additional","affiliation":[]},{"given":"K","family":"Korn","sequence":"additional","affiliation":[]},{"given":"B","family":"Masquelier","sequence":"additional","affiliation":[]},{"given":"CF","family":"Perno","sequence":"additional","affiliation":[]},{"given":"JM","family":"Schapiro","sequence":"additional","affiliation":[]},{"given":"V","family":"Soriano","sequence":"additional","affiliation":[]},{"given":"A","family":"S\u00f6nnerborg","sequence":"additional","affiliation":[]},{"given":"A-M","family":"Vandamme","sequence":"additional","affiliation":[]},{"given":"C","family":"Verhofstede","sequence":"additional","affiliation":[]},{"given":"H","family":"Walter","sequence":"additional","affiliation":[]},{"given":"M","family":"Zazzi","sequence":"additional","affiliation":[]},{"given":"CAB","family":"Boucher","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1473-3099(10)70319-4_bib1","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/S1473-3099(10)70319-4_bib3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1099\/0022-1317-83-8-1809","article-title":"Cell surface receptors, virus entry and tropism of primate lentiviruses","volume":"83","author":"Clapham","year":"2002","journal-title":"J Gen Virol"},{"key":"10.1016\/S1473-3099(10)70319-4_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/088922204322749567","article-title":"The CCR5 and CXCR4 coreceptors\u2014central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection","volume":"20","author":"Moore","year":"2004","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/S1473-3099(10)70319-4_bib5","unstructured":"McGeehan K, Polacchini de Oliveira A, Hoxie J. Effects of HIV-1 variants containing partial deletions within the V3 loop on co-receptor tropism and sensitivity to entry inhibitors. 14th Conference on Retroviruses and Opportunistic Infections; Los Angeles, CA, USA; Feb 25\u201328, 2007. Abstract 181a."},{"key":"10.1016\/S1473-3099(10)70319-4_bib6","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1089\/aid.1998.14.1129","article-title":"Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication","volume":"14","author":"Stamatatos","year":"1998","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/S1473-3099(10)70319-4_bib7","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1073\/pnas.94.8.4005","article-title":"Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains","volume":"94","author":"Edinger","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S1473-3099(10)70319-4_bib8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/sj.emboj.7600947","article-title":"HIV and the chemokine system: 10 years later","volume":"25","author":"Lusso","year":"2006","journal-title":"EMBO J"},{"key":"10.1016\/S1473-3099(10)70319-4_bib9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/34571","article-title":"A new classification for HIV-1","volume":"391","author":"Berger","year":"1998","journal-title":"Nature"},{"key":"10.1016\/S1473-3099(10)70319-4_bib10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/aid.2006.0130","article-title":"Structural basis for coreceptor selectivity by the HIV type 1 V3 loop","volume":"23","author":"Cardozo","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/S1473-3099(10)70319-4_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2334-2-31","article-title":"Infection of cells expressing CXCR4 mutants lacking N-glycosylation at the N-terminal extracellular domain is enhanced for R5X4-dualtropic human immunodeficiency virus type-1","volume":"2","author":"Thordsen","year":"2002","journal-title":"BMC Infect Dis"},{"key":"10.1016\/S1473-3099(10)70319-4_bib12","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1084\/jem.194.11.1661","article-title":"Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines","volume":"194","author":"Bannert","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/S1473-3099(10)70319-4_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0005-2736(03)00162-7","article-title":"HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors","volume":"1614","author":"Zaitseva","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/S1473-3099(10)70319-4_bib14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev.med.58.080105.102908","article-title":"Chemokine antagonists as therapeutics: focus on HIV-1","volume":"58","author":"Tsibris","year":"2007","journal-title":"Annu Rev Med"},{"key":"10.1016\/S1473-3099(10)70319-4_bib15","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/591623","article-title":"Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study","volume":"198","author":"Shepherd","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/S1473-3099(10)70319-4_bib16","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1310\/hct1006-394","article-title":"Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain","volume":"10","author":"Moreno","year":"2009","journal-title":"HIV Clin Trials"},{"key":"10.1016\/S1473-3099(10)70319-4_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1089\/aid.2007.0140","article-title":"CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals","volume":"24","author":"Low","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/S1473-3099(10)70319-4_bib18","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/jmv.20900","article-title":"Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy","volume":"79","author":"Poveda","year":"2007","journal-title":"J Med Virol"},{"key":"10.1016\/S1473-3099(10)70319-4_bib19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1089\/aid.2008.0252","article-title":"Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals","volume":"25","author":"Huang","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/S1473-3099(10)70319-4_bib20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/QAI.0b013e3181734f0e","article-title":"Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters","volume":"48","author":"de Mendoza","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/S1473-3099(10)70319-4_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/QAI.0b013e31819fb903","article-title":"Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4\/X4 viruses in plasma","volume":"51","author":"Soulie","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/S1473-3099(10)70319-4_bib22","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1089\/aid.2009.0069","article-title":"Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates","volume":"25","author":"Karlsson","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/S1473-3099(10)70319-4_bib23","unstructured":"Spudich S, Gisslen M, Hagberg L, et al. Cerebrospinal fluid compartmentalization of HIV-1 replication capacity and co-receptor tropism differ between early and chronic infection. 16th Conference On Retroviruses and Opportunistic Infections; Montreal, Canada; Feb 8\u201311, 2009. Abstract 469."},{"key":"10.1016\/S1473-3099(10)70319-4_bib24","unstructured":"Ince W, Harrington P, Dang K, et al. HIV-1 viruses with different co-receptor tropisms are not highly compartmentalized in the peripheral blood. 15th Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; Feb 3\u20136, 2008. Abstract 249."},{"key":"10.1016\/S1473-3099(10)70319-4_bib25","unstructured":"Skaria A, Brumme Z, Sela J, et al. Compartmentalization of drug resistance, immune escape, and co-receptor tropism in circulating plasma viruses during late-stage HIV infection. 16th Conference On Retroviruses and Opportunistic Infections; Montreal, Canada; Feb 8\u201311, 2009. Abstract 415."},{"issue":"12 suppl","key":"10.1016\/S1473-3099(10)70319-4_bib26","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/nrmicro1570","article-title":"Evaluation of diagnostic tests for infectious diseases: general principles","volume":"4","author":"Banoo","year":"2006","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/S1473-3099(10)70319-4_bib27","first-page":"317","article-title":"Determination of cell tropism of HIV-1","volume":"304","author":"Kootstra","year":"2005","journal-title":"Methods Mol Biol"},{"key":"10.1016\/S1473-3099(10)70319-4_bib28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1128\/AAC.00853-06","article-title":"Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism","volume":"51","author":"Whitcomb","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S1473-3099(10)70319-4_bib29","unstructured":"Hamy F, Gacia O, Klimkait T. Coreceptor tropism of HIV in clinical samples dissected by rPhenotyping. 4th International AIDS Society Conference; Sydney, Australia; July 22\u201325, 2007. Abstract WEPEA009."},{"key":"10.1016\/S1473-3099(10)70319-4_bib30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jcv.2009.11.018","article-title":"Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage","volume":"47","author":"Raymond","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/S1473-3099(10)70319-4_bib31","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/648090","article-title":"Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211","volume":"200","author":"Su","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/S1473-3099(10)70319-4_bib32","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/jac\/dkp063","article-title":"Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists","volume":"63","author":"Poveda","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/S1473-3099(10)70319-4_bib33","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1093\/jac\/dkq137","article-title":"High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists","volume":"65","author":"Secl\u00e9n","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/S1473-3099(10)70319-4_bib34","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/jmv.21425","article-title":"Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools","volume":"81","author":"Chueca","year":"2009","journal-title":"J Med Virol"},{"key":"10.1016\/S1473-3099(10)70319-4_bib35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/aid.2008.0039","article-title":"Robust supervised and unsupervised statistical learning for HIV type 1 coreceptor usage analysis","volume":"25","author":"Prosperi","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/S1473-3099(10)70319-4_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1293.2008.00518.x","article-title":"Comparison of two genotypic algorithms to determine HIV-1 tropism","volume":"9","author":"Soulie","year":"2008","journal-title":"HIV Med"},{"key":"10.1016\/S1473-3099(10)70319-4_bib37","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/JCM.01118-06","article-title":"Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model","volume":"45","author":"Skrabal","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/S1473-3099(10)70319-4_bib38","doi-asserted-by":"crossref","first-page":"e5683","DOI":"10.1371\/journal.pone.0005683","article-title":"Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo","volume":"4","author":"Tsibris","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/S1473-3099(10)70319-4_bib39","unstructured":"Toma T, Frantzell T, Hoh R, et al. Determining HIV-1 coreceptor tropism using PBMC proviral DNA derived from aviremic blood samples. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; Feb 27\u2013March 2, 2010. Abstract 541."},{"issue":"suppl","key":"10.1016\/S1473-3099(10)70319-4_bib40","first-page":"84","article-title":"The Berlin Maraviroc cohort\u2014influence of genotypic tropism testing results on therapeutic outcome. 7th European HIV Drug Resistance Workshop; Stockholm, Sweden; March 27\u201329, 2009. Abstract 79","volume":"1","author":"Obermeier","year":"2009","journal-title":"Rev Antivir Ther"},{"issue":"suppl","key":"10.1016\/S1473-3099(10)70319-4_bib41","first-page":"85","article-title":"Genotypic prediction of viral co-receptor tropism: correlation with enhanced Trofile. 7th European HIV Drug Resistance Workshop; Stockholm, Sweden; March 27\u201329, 2009. Abstract 80","volume":"1","author":"Strang","year":"2009","journal-title":"Rev Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib42","unstructured":"Swenson LC, Dong W, Mo T, et al. Large-scale application of \u201cdeep\u201d sequencing using 454 technology to HIV tropism screening. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; Feb 27\u2013March 2, 2010. Abstract 454."},{"key":"10.1016\/S1473-3099(10)70319-4_bib43","unstructured":"McGovern R, Dong W, Zhong X, Knapp D, Thielen A, Chapman D. Population-based sequencing of the V3-loop is comparable to the enhanced sensitivity Trofile assay in predicting virologic response to maraviroc of treatment-naive patients in the MERIT trial. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; Feb 27\u2013March 2, 2010. Abstract 92."},{"key":"10.1016\/S1473-3099(10)70319-4_bib44","first-page":"23","article-title":"Tropism testing from proviral DNA\u2014analysis of a subgroup from the Berlin Maraviroc cohort. 8th European HIV Drug Resistance Workshop; Sorrento, Italy; March 17\u201319, 2010. Abstract 23","volume":"1","author":"Obermeier","year":"2010","journal-title":"Rev Antivir Ther"},{"issue":"suppl","key":"10.1016\/S1473-3099(10)70319-4_bib45","first-page":"A51","article-title":"Genotypic and phenotypic HIV Tropism testing predicts the outcome of maraviroc regimens","volume":"14","author":"Braun","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib46","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1128\/AAC.00148-10","article-title":"Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study","volume":"54","author":"Recordon-Pinson","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S1473-3099(10)70319-4_bib47","unstructured":"Pou C, Codo\u00f1er F, Thielen A, et al. High resolution tropism kinetics by quantitative deep sequencing in HIV-1-infected subjects initiating suppressive first-line antiretroviral therapy. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; Feb 27\u2013March 2, 2010. Abstract 544."},{"key":"10.1016\/S1473-3099(10)70319-4_bib48","first-page":"42","article-title":"Use of a genotypic assay for prediction of HIV-1 co-receptor tropism and guiding the use of CCR5 antagonists in clinical practice. 8th European HIV Drug Resistance Workshop; Sorrento, Italy; March 17\u201319, 2010. Abstract 44","volume":"1","author":"Macartney","year":"2010","journal-title":"Rev Antivir Ther Infect Dis"},{"key":"10.1016\/S1473-3099(10)70319-4_bib49","unstructured":"Swenson LCD, Dong W, Mo T. et al. \u201cDeep\u201d sequencing to identify treatment-experienced patients who respond to maraviroc (MVC). 12th European AIDS Conference; Cologne, Germany; Nov 11\u201314, 2009. Abstract PE3 3\/2."},{"key":"10.1016\/S1473-3099(10)70319-4_bib50","first-page":"22","article-title":"Low detection of non-ccr5 using strains by ultra deep sequencing does not compromise response to a maraviroc containing regimen. 8th European HIV Drug Resistance Workshop; Sorrento, Italy; March 17\u201319, 2010. Abstract 22","volume":"1","author":"Garcia","year":"2010","journal-title":"Rev Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2174\/1874357900802010008","article-title":"Minor variant detection at different template concentrations in HIV-1 phenotypic and genotypic tropism testing","volume":"2","author":"Vandenbroucke","year":"2008","journal-title":"Open Virol J"},{"key":"10.1016\/S1473-3099(10)70319-4_bib52","first-page":"440","article-title":"FDA approves drug for resistant HIV","volume":"17","year":"2007","journal-title":"AIDS Read"},{"key":"10.1016\/S1473-3099(10)70319-4_bib53","unstructured":"Lewis M, Simpson P, Xiting L, Robertson D, Whitcomb J, Westby M. Dual-tropic virus clones from patients enrolled in the MOTIVATE studies, may respond differently in vivo to maraviroc based on their V3 loop sequence. 6th European HIV Drug Resistance Workshop; Budapest, Hungary; March 26\u201328, 2008. Abstract 50."},{"key":"10.1016\/S1473-3099(10)70319-4_bib54","unstructured":"Palleja S, Cohen C, Gathe J, Thompson M, DeJesus E, Brinson C. Safety and efficacy of TBR 652, a CCR5 antagonist, in HIV-1-infected, ART-experienced, CCR5 antagonist-naive patients. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; Feb 27\u2013March 2, 2010. Abstract 53."},{"key":"10.1016\/S1473-3099(10)70319-4_bib55","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/AAC.00821-07","article-title":"Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)","volume":"52","author":"Nichols","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S1473-3099(10)70319-4_bib56","first-page":"181","article-title":"Discontinuation of aplaviroc trials due to hepatotoxicity","volume":"7","author":"Blanco","year":"2005","journal-title":"AIDS Rev"},{"key":"10.1016\/S1473-3099(10)70319-4_bib57","unstructured":"Gathe J, Diaz R, Fatkenheuer G, et al. Phase 3 trials of vicriviroc in treatment-experienced subjects demonstrate safety but not significantly superior efficacy over potent background regimens alone. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; Feb 27\u2013March 2, 2010. Abstract 54 LB."},{"key":"10.1016\/S1473-3099(10)70319-4_bib58","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/QAD.0b013e3282ef81ea","article-title":"Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates","volume":"21","author":"Low","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/S1473-3099(10)70319-4_bib59","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1128\/JCM.01611-07","article-title":"Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes","volume":"46","author":"Garrido","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/S1473-3099(10)70319-4_bib60","author":"Walter"},{"key":"10.1016\/S1473-3099(10)70319-4_bib61","first-page":"36","article-title":"The influence of PCR amplification variation on the ability of population-based PCR to detect non-R5 HIV. 8th European HIV Drug Resistance Workshop; Sorrento, Italy; March 17\u201319, 2010. Abstract 38","volume":"1","author":"Harrigan","year":"2010","journal-title":"Rev Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib62","unstructured":"McGovern R, Dong W, Mo T, et al. Optimization of clinically relevant cutpoints for the determination of HIV co-receptor usage to predict maraviroc responses in treatment experienced (TE) patients using population V3 genotyping. 12th European AIDS Conference. Cologne, Germany; Nov 11\u201314, 2009. Abstract PE3.4\/8."},{"key":"10.1016\/S1473-3099(10)70319-4_bib63","unstructured":"Thielen A, Harrigan PR, Low AJ, et al. Improved genotypic prediction of HIV-1 coreceptor usage by incorporating V2 loop sequence variation. 17th International HIV Drug Resistance Workshop. Sitges, Spain; June 10\u201314, 2008. Abstract 90."},{"key":"10.1016\/S1473-3099(10)70319-4_bib64","first-page":"47","article-title":"Mutations within GP41 are correlated with coreceptor tropism but do not substantially improve coreceptor usage prediction. 8th European HIV Drug Resistance Workshop; Sorrento, Italy; March 17\u201319, 2010. Abstract 49","volume":"1","author":"Thielen","year":"2010","journal-title":"Rev Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib65","unstructured":"Stawiski E, Huang W, Whitcomb J, Napolitano L, Petropoulos C, Coakley E. Amino acid changes in gp41 of HIV-1 associated with coreceptor tropism. 18th International HIV Drug Resistance Workshop Basic Principles and Clinical Implications; Fort Myers, FL, USA; June 9\u201313, 2009. Abstract 114."},{"key":"10.1016\/S1473-3099(10)70319-4_bib66","unstructured":"Waters L, Scourfield A, Marcano M, Gazzard B, Nelson M. The evolution of co-receptor tropism in patients interrupting suppressive HAART. 16th Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; Feb 8\u201311, 2009. Abstract 439a."},{"key":"10.1016\/S1473-3099(10)70319-4_bib67","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/dkm469","article-title":"Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years","volume":"61","author":"Briz","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/S1473-3099(10)70319-4_bib68","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/QAD.0b013e3282f0e3d0","article-title":"HIV-1 X4\/R5 co-receptor in viral reservoir during suppressive HAART","volume":"21","author":"Soulie","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/S1473-3099(10)70319-4_bib69","first-page":"55","volume":"1","author":"Bracciale","year":"2009","journal-title":"Rev Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib70","first-page":"86","article-title":"Correlation between population based-sequencing and viral tropism determination on PBMC DNA and plasma RNA in comparison with phenotypic methods. 7th European HIV Drug Resistance Workshop; Stockholm, Sweden; March 27\u201329, 2009. Abstract 81","volume":"1","author":"Verhofstede","year":"2009","journal-title":"Rev Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib71","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/dkp151","article-title":"High frequency of X4\/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996\u20132007: the French ANRS CO06 PRIMO Cohort Study","volume":"64","author":"Frange","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/S1473-3099(10)70319-4_bib72","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/QAI.0b013e31819118fa","article-title":"CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA","volume":"50","author":"Verhofstede","year":"2009","journal-title":"Journal of acquired immune deficiency syndromes"},{"key":"10.1016\/S1473-3099(10)70319-4_bib73","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/jac\/dkq029","article-title":"Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists","volume":"65","author":"Soulie","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/S1473-3099(10)70319-4_bib74","unstructured":"Whitcomb J, Huang W, Fransen S. Characterization and validation of Trofile, an assay to determine HIV coreceptor tropism. 2nd International Workshop on Targeting HIV Entry; Boston, MA, USA; Oct 20\u201321, 2006. Abstract 26."},{"key":"10.1016\/S1473-3099(10)70319-4_bib75","unstructured":"Napolitano L, Tressler T, Coakley E, Santos C, Heera J, Whitcomb J. Incorporation of optimized primers into the Trofile assay substantially improves determination of viral tropism in genetically diverse hiv subtypes. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, USA; Sept 12\u201315, 2009. Abstract 908."},{"key":"10.1016\/S1473-3099(10)70319-4_bib76","first-page":"89","article-title":"Evaluation of the sensitivity and specificity of population V3 sequencing and tropism prediction in comparison with 454 deep sequencing. 8th European HIV Drug Resistance Workshop; Sorrento, Italy; March 17\u201319, 2010. Abstract 84","volume":"1","author":"Verhofstede","year":"2009","journal-title":"Rev Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib77","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jviromet.2004.09.003","article-title":"A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene","volume":"123","author":"Van Laethem","year":"2005","journal-title":"J Virol Methods"},{"key":"10.1016\/S1473-3099(10)70319-4_bib78","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1093\/bioinformatics\/bti654","article-title":"Computational methods for the design of effective therapies against drug resistant HIV strains","volume":"21","author":"Beerenwinkel","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/S1473-3099(10)70319-4_bib79","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAI.0b013e3181c8413b","article-title":"Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses","volume":"53","author":"Raymond","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/S1473-3099(10)70319-4_bib80","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1128\/JVI.80.10.4698-4704.2006","article-title":"A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences","volume":"80","author":"Jensen","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/S1473-3099(10)70319-4_bib81","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1128\/JCM.02439-08","article-title":"Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism","volume":"47","author":"Raymond","year":"2009","journal-title":"J Clin Microbiol"},{"key":"10.1016\/S1473-3099(10)70319-4_bib82","first-page":"99","volume":"1","author":"Thielen","year":"2009","journal-title":"Rev Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib83","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa0803154","article-title":"Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection","volume":"359","author":"Fatkenheuer","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/S1473-3099(10)70319-4_bib84","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/S1473-3099(10)70319-4_bib85","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/598965","article-title":"A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1","volume":"199","author":"Saag","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/S1473-3099(10)70319-4_bib86","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1310\/hct1103-125","article-title":"Efficacy and safety of maraviroc versus efavirenz, both with zidovudine\/lamivudine: 96-week results from the MERIT study","volume":"11","author":"Sierra-Madero","year":"2010","journal-title":"HIV Clin Trials"},{"key":"10.1016\/S1473-3099(10)70319-4_bib87","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1086\/650697","article-title":"Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection","volume":"201","author":"Cooper","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/S1473-3099(10)70319-4_bib88","unstructured":"Swenson LC, McGovern AR, Dong W, et al. Phenotypic screening for HIV tropism versus both population-based and \u201cdeep\u201d sequencing. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, USA; Sept 12\u201315, 2009. Abstract H-899\/378."},{"key":"10.1016\/S1473-3099(10)70319-4_bib89","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1086\/592052","article-title":"Phase II study of vicriviroc versus efavirenz (both with zidovudine\/lamivudine) in treatment-naive subjects with HIV-1 infection","volume":"198","author":"Landovitz","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/S1473-3099(10)70319-4_bib90","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1086\/650342","article-title":"Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial","volume":"201","author":"Suleiman","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/S1473-3099(10)70319-4_bib91","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1086\/518797","article-title":"Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211","volume":"196","author":"Gulick","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/S1473-3099(10)70319-4_bib92","unstructured":"Hosoya N, Su Z, Wilkin T, et al. Assessing HIV-1 tropism in ACTG A5211: a comparison of assays using replication-competent virus from peripheral blood mononuclear cells vs plasma-derived pseudotyped virions. 14th Conference on Retroviruses and Opportunistic Infections; Los Angeles, CA, USA; Feb 25\u201328, 2007. Abstract 181b."},{"key":"10.1016\/S1473-3099(10)70319-4_bib93","first-page":"91","article-title":"Comparison of Trofile and MT-2 assay in the clinical practice of maraviroc containing therapy. 7th European HIV Drug Resistance Workshop; Stockholm, Sweden; March 27\u201329, 2009. Abstract 87","volume":"1","author":"van Lelyveld","year":"2009","journal-title":"Rev Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib94","first-page":"23","article-title":"Tropism testing from proviral DNA\u2014analysis of a subgroup from the Berlin Maraviroc cohort. 8th European HIV Drug Resistance Workshop; Sorrento, Italy; March 17\u201319, 2010. Abstract 23","volume":"1","author":"Obermeier","year":"2010","journal-title":"Rev Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib95","first-page":"20","article-title":"Tropism determination and clinical outcome of 61 patients under MVC treatment. 8th European HIV Drug Resistance Workshop; Sorrento, Italy; March 17\u201319, 2010. Abstract 20","volume":"1","author":"Sierra","year":"2010","journal-title":"Rev Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib96","first-page":"87","article-title":"Co-receptor tropism prediction in chronically HIV-1-infected subjects with suppressed viremia. 7th European HIV Drug Resistance Workshop; Stockholm, Sweden; March 27\u201329, 2009. Abstract 82","volume":"1","author":"Pou","year":"2009","journal-title":"Rev Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib97","doi-asserted-by":"crossref","first-page":"F11","DOI":"10.1097\/QAD.0b013e32830ebcd4","article-title":"Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism","volume":"22","author":"Raymond","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/S1473-3099(10)70319-4_bib98","unstructured":"Chueca N, Alvarez M, Guillot V, et al. Inference of coreceptor usage by V3 gene sequencing and a combination of bioinformatics tools. 4th International Conference Targeting HIV Entry; Rio Grande, Puerto Rico; Dec 8\u20139, 2008. Abstract 7."},{"key":"10.1016\/S1473-3099(10)70319-4_bib99","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1128\/AAC.00229-09","article-title":"Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays","volume":"53","author":"Coakley","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/S1473-3099(10)70319-4_bib100","first-page":"90","article-title":"Sequence and structure information of Env-V3 forms the basis for a sensitive genosorting method to determine HIV coreceptor use. 7th European HIV Drug Resistance Workshop; Stockholm, Sweden; March 27\u201329. Abstract 85","volume":"1","author":"Klimkait","year":"2009","journal-title":"Rev Antivir Ther"},{"key":"10.1016\/S1473-3099(10)70319-4_bib101","unstructured":"Svicher V, Cammarota R, Artese A, et al. New V3-genetic signatures modulate co-receptor usage in vivo and the interaction with CCR5 N-terminus. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; Feb 27\u2013March 2, 2010. Abstract 542."},{"key":"10.1016\/S1473-3099(10)70319-4_bib102","unstructured":"Shulman N, Johnston E, Winters M, Katzenstein D. Measuring HIV coreceptor tropism and SI phenotype in archived samples: a comparison of different methods. 13th Conference on Retroviruses and Opportunistic Infections; Denver, CO, USA; Feb 5\u20138, 2006. Abstract 657."},{"key":"10.1016\/S1473-3099(10)70319-4_bib103","unstructured":"Saag M, Heera J, Goodrich J. Reanalysis of the MERIT study with the enhanced Trofile assay (MERIT-ES). 48th Annual ICAAC\/IDSA 46th Annual Meeting' Washington, DC, USA; Oct 25\u201328, 2008. Abstract H-1232a."},{"key":"10.1016\/S1473-3099(10)70319-4_bib104","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/jac\/dkp113","article-title":"Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients","volume":"63","author":"Vandekerckhove","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/S1473-3099(10)70319-4_bib105","first-page":"35","article-title":"Challenges in predicting HIV-1 co-receptor tropism from V3 region genotype data. 4th European HIV Drug Resistance Workshop. Monte Carlo, Monaco; March 29\u201331, 2006. Abstract 31","volume":"2","author":"Stawiski","year":"2006","journal-title":"Rev Antivir Ther"}],"container-title":["The Lancet Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473309910703194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473309910703194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T09:10:53Z","timestamp":1761469853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473309910703194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":104,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1473309910703194"],"URL":"https:\/\/doi.org\/10.1016\/s1473-3099(10)70319-4","relation":{},"ISSN":["1473-3099"],"issn-type":[{"value":"1473-3099","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European guidelines on the clinical management of HIV-1 tropism testing","name":"articletitle","label":"Article Title"},{"value":"The Lancet Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1473-3099(10)70319-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}